Viyash Scientific Limited

rs,

Proven Ability In Life Sciences November 14, 2025 To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001 National Stock Exchange of India Limited Exchange Plaza, B

₹8,521 Million

rmance Highlights Revenues EBITDA1 EBITDA margin All values in ₹ Mn Net Debt to LTM EBITDA1 ₹8,521 Million ₹1,890 Million 22.2% 0.7x +16 % YoY +76% YoY +750 bps YoY 1.4x in Q2 FY25 Notes: 1. EBITD

₹1,890 Million

s Revenues EBITDA1 EBITDA margin All values in ₹ Mn Net Debt to LTM EBITDA1 ₹8,521 Million ₹1,890 Million 22.2% 0.7x +16 % YoY +76% YoY +750 bps YoY 1.4x in Q2 FY25 Notes: 1. EBITDA for Viyash and

22.2%

ITDA1 EBITDA margin All values in ₹ Mn Net Debt to LTM EBITDA1 ₹8,521 Million ₹1,890 Million 22.2% 0.7x +16 % YoY +76% YoY +750 bps YoY 1.4x in Q2 FY25 Notes: 1. EBITDA for Viyash and SeQuen

0.7x

EBITDA margin All values in ₹ Mn Net Debt to LTM EBITDA1 ₹8,521 Million ₹1,890 Million 22.2% 0.7x +16 % YoY +76% YoY +750 bps YoY 1.4x in Q2 FY25 Notes: 1. EBITDA for Viyash and SeQuent are

16 %

margin All values in ₹ Mn Net Debt to LTM EBITDA1 ₹8,521 Million ₹1,890 Million 22.2% 0.7x +16 % YoY +76% YoY +750 bps YoY 1.4x in Q2 FY25 Notes: 1. EBITDA for Viyash and SeQuent are adjuste

76%

values in ₹ Mn Net Debt to LTM EBITDA1 ₹8,521 Million ₹1,890 Million 22.2% 0.7x +16 % YoY +76% YoY +750 bps YoY 1.4x in Q2 FY25 Notes: 1. EBITDA for Viyash and SeQuent are adjusted for ESOP

750 bps

₹ Mn Net Debt to LTM EBITDA1 ₹8,521 Million ₹1,890 Million 22.2% 0.7x +16 % YoY +76% YoY +750 bps YoY 1.4x in Q2 FY25 Notes: 1. EBITDA for Viyash and SeQuent are adjusted for ESOP costs Source:

1.4x

bt to LTM EBITDA1 ₹8,521 Million ₹1,890 Million 22.2% 0.7x +16 % YoY +76% YoY +750 bps YoY 1.4x in Q2 FY25 Notes: 1. EBITDA for Viyash and SeQuent are adjusted for ESOP costs Source: Viyash Li

rs 3

for ESOP costs Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers 3 Sequent + Viyash : Combined H1 FY26 Performance Highlights Revenues EBITDA1 EBITDA margin All v

₹16,462 Million

rmance Highlights Revenues EBITDA1 EBITDA margin All values in ₹ Mn Net Debt to LTM EBITDA1 ₹16,462 Million ₹3,810 Million 19.3% 0.7x +12.5 % YoY +48 % YoY +460 bps YoY 1.4x in H1 FY25 Notes: 1. EB

₹3,810 Million

Revenues EBITDA1 EBITDA margin All values in ₹ Mn Net Debt to LTM EBITDA1 ₹16,462 Million ₹3,810 Million 19.3% 0.7x +12.5 % YoY +48 % YoY +460 bps YoY 1.4x in H1 FY25 Notes: 1. EBITDA for Viyash

“Viyash EBITDA is adjusted for ESOP costs ₹533 Million Q2 FY25 Loss (82mn) 12 Viyash: Q2 FY26 Key growth drivers New product launches Focus on CDMO business Improved product mix Network optimisation for better efficiencies Backward and Forward integration 13 Viyash: H1FY26 Business Performance Revenues EBITDA1 EBITDA1 margin PAT ₹7,808 Million ₹1,921 Million 11.0% YoY 58.9% YoY 24.6% 741 bps YoY Note: 1.”

“H1FY26 YoY growth of 11% o Gross Margin improved to 61.1% in Q2FY26 from 54.7% in FY25 and 58% in Q1FY26 o EBITDA % improved to 28.8% in Q2 FY26 from 17.5 % in FY25 and 19.5% in Q1FY26 o Significant improvement in profit before tax, profit after tax.”

“This accounting amortization will continue till FY27 Exceptional Items include cost of accelerated vesting for share warrants, call option charge, merger expenses (Viyash) and one-time contractual bonus payable to Viyash management (Viyash) PAT adjusted for Amortization of acquisition intangibles and Exceptional Items (net of tax) Adjusted for ESOP costs 1.”

Emerging Markets

1

Key Notes

1

Emerging Markets

▪ Launched Tulaject in Brazil & received MA for Mexico market ▪ R&D infrastructure expanded India: Business beginning to accelerate as field team expansion ramps up Business momentum continues, ~7% YoY growth Launched a product for the US market API Completed successful audits for large customers SRL USFDA audit completed – EIR awaited 1,000+ FDFs 90+ Countries 5 Manufacturing Facilities 35 APIs 50+ Countries 2 Manufacturing facilities Sequent Consolidated Financials Particulars Revenue from Operations Material Consumption Gross Margin % Employee Benefit Expenses Operating Expenses EBITDA1 % ESOP cost Exceptional Items IndAS 29 Adjustment Exchange Gain / (Loss) Other Income Finance Cost Depreciation Earnings Before Tax Taxes Earnings After Tax Q2 FY26 4,240 (2,131) 2,109 49.7% (731) (721) 657 15.5% (86) (17) (7) (7) 22 (135) (155) 272 (76) 196 Q2 FY25 3,686 (1,953) 1,734 47.0% (603) (683) 447 12.1% (67) (43) 25 (14) 45 (143) (171) 79 (16) 63 Grw YoY % 15.0% 21.6% 21.2% 5.5% 47.0% 243.7

Key Notes

ESOP cost, Exceptional items and amortization of acquisition intangibles are non-cash or non-recurring accounting items that pertain to prior period events: - Exceptional Items include cost of accelerated vesting for share warrants, call option charge, merger expenses and provision for a contractual one-time bonus payable at Viyash - Amortization of acquisition intangibles in Viyash is on account of intangibles created during acquisitions done in FY22. This accounting amortization will continue till FY27 Exceptional Items include cost of accelerated vesting for share warrants, call option charge, merger expenses (Viyash) and one-time contractual bonus payable to Viyash management (Viyash) PAT adjusted for Amortization of acquisition intangibles and Exceptional Items (net of tax) Adjusted for ESOP costs 1. 2. 3. Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers 19 Merger – Process Update Merger process status update • CCI approval and Stock Exchange